Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Nov-Dec;33(9):983-90.
doi: 10.1097/CJI.0b013e3181f3cbf4.

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

Chrystal U Louis  1 , Karin Straathof, Catherine M Bollard, Sravya Ennamuri, Claudia Gerken, Teresita T Lopez, M Helen Huls, Andrea Sheehan, Meng-Fen Wu, Hao Liu, Adrian Gee, Malcolm K Brenner, Cliona M Rooney, Helen E Heslop, Stephen Gottschalk
Affiliations
Clinical Trial

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

Chrystal U Louis et al. J Immunother. 2010 Nov-Dec.

Abstract

Patients with recurrent or refractory Epstein Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) continue to have poor outcomes. Our earlier Phase I dose escalation clinical study of 10 NPC patients showed that infusion of EBV-specific cytotoxic T cells (EBV-CTLs) was safe and had antitumor activity. To better define the overall response rate and discover whether disease status, EBV-antigen specificity, and/or in vivo expansion of infused EBV-CTLs predicted outcome, we treated 13 additional NPC patients with EBV-CTLs in a fixed-dose, Phase II component of the study. We assessed toxicity, efficacy, specificity, and expansion of infused CTLs for all 23 recurrent/refractory NPC patients treated on this Phase I/II clinical study. At the time of CTL infusion, 8 relapsed NPC patients were in remission and 15 had active disease. No significant toxicity was observed. Of the relapsed patients treated in their second or subsequent remission, 62% (5/8) remain disease free (at 17 to 75 mo), whereas 48.7% (7/15) of those with active disease had a CR/CRu (33.3%) or PR (15.4%). In contrast to locoregional disease, metastatic disease was associated with an increased risk of disease progression (HR: 3.91, P=0.015) and decreased overall survival (HR: 5.55, P=0.022). Neither the specificity of the infused CTLs for particular EBV antigens nor their measurable in vivo expansion discernibly influenced outcome. In conclusion, treatment of patients with relapsed/refractory EBV-positive NPC with EBV-CTLs is safe and can be associated with significant, long-term clinical benefit, particularly for patients with locoregional disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Transient increase of LMP2-specific T-cell frequency after EBV-CTL infusion
The frequency of (A) EBV-, (B) LMP2-, and (C) CMV-specific T cells was determined using ELIspot assays. There was a trend towards increased LMP2-specific T cells (p=0.081) at 2 weeks after CTL infusion (- -: individual patients; –: median; NED: no evidence of disease).
Figure 2
Figure 2. Clinical response after EBV-CTL infusion
PET images of patient (P1668) before and 8 weeks after EBV-specific CTL infusion.
Figure 3
Figure 3. Overall and progression-free survival after EBV-CTL infusion
A) Overall survival, B) Overall survival by disease status at 1st CTL infusion, C) Progression-free survival, D) Progression by disease status at 1st CTL infusion (p-value: metastatic disease vs. remission).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 2002;13:1007–15. - PubMed
    1. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol. 2002;12:431–41. - PubMed
    1. Mould RF, Tai TH. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Br J Radiol. 2002;75:307–39. - PubMed
    1. Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003;4:13–21. - PubMed
    1. Lee CC, Huang TT, Lee MS, et al. Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome. Radiat Oncol. 2010;5:20. - PMC - PubMed

Publication types

MeSH terms

Substances